scispace - formally typeset
Search or ask a question

Answers from top 10 papers

More filters
Papers (10)Insight
In this article, Dr. Johnson adds a considerable amount of light to the limitations and hazards of genetic predictions based on DNA probes.
The results could allow the company, which is being acquired by Johnson & Johnson, to develop third-generation molecules that overcome the resistance mechanism.
The fusion sequence at the novel exon-exon boundary, and the absence of corresponding DNA rearrangement suggest that this chimeric RNA is likely produced by trans-splicing in human cells. ReviewersThis article was reviewed by Rory Johnson (nominated by Fyodor Kondrashov); Gal Avital and Itai Yanai
These assays are likely just the tip of the proverbial iceberg as some large pharmaceutical companies with significant resources (eg, Johnson and Johnson)
These data suggest that the Johnson et al.
This unique partnership has aided SC Johnson by more directly linking consumer and company environmental objectives to the new product development process.
Thus, many obstacles to the use of the Johnson System are resolved.
Of the two, Johnson is the more interesting as a character.
This supports the conclusion of Johnson et al.
Crucially, independent confirmation of the findings of Johnson et al.